A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer.

ABSTRACT:

Background

Pemetrexed and cisplatin is a first-line standard in non-squamous non-small-cell lung cancer without targetable mutations. It became the backbone of checkpoint-inhibitor-chemotherapy combinations. Single high doses of cisplatin pose toxicity risks and require hyperhydration, potentially prolonging outpatient application. The aim of this study was to compare efficacy, safety and tolerability of split-dose cisplatin with the standard schedule.

Methods

Patients with metastatic non-squamous non-small-cell lung cancer were randomly assigned to up to six 21-day cycles of pemetrexed 500 mg/m² and cisplatin 75 mg/m² on day 1 (arm A), or pemetrexed 500 mg/m² (day 1) and cisplatin 40 mg/m² (day 1 + 8, arm B), followed by pemetrexe

SUBMITTER: Metzenmacher M 

PROVIDER: S-EPMC8164550 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature